We then selected Pt1 and Pt2 for further analysis because, showing a very different sensitivity to vemurafenib (IC50 6124.18 and 399.41 nm, respectively), they could represent the paradigmatic condition of melanoma patients: initial disease regression after BRAFi treatment (Pt2) and subsequent appearance of relapse due to development of resistance (Pt1). The gene discussed is ZNF77; the disease is melanoma.